Core Insights - Palvella Therapeutics is advancing its QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with a New Drug Application (NDA) submission planned for the second half of 2026, potentially becoming the first FDA-approved therapy for this condition affecting over 30,000 patients in the U.S. [1][4] Research and Development Highlights - Positive topline results from the Phase 3 SELVA study for QTORIN™ rapamycin were reported, meeting the primary endpoint with a mean change of +2.13 (p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) [5] - 95% of trial participants aged 6 years and older showed improvement on the mLM-IGA at Week 24, with 86% rated as "Much Improved" or "Very Much Improved" [5] - QTORIN™ rapamycin was well-tolerated, with no serious adverse events reported and systemic levels below 2ng/mL [5] - Initiation of Phase 3 trial for cutaneous venous malformations and Phase 2 trials for clinically significant angiokeratomas and disseminated superficial actinic porokeratosis are planned for the second half of 2026 [2][12] Financial Overview - As of December 31, 2025, the company reported pro forma cash of approximately $274 million, reflecting net proceeds from a February 2026 equity financing [2][17] - Research and development expenses for 2025 were $22.8 million, up from $8.2 million in 2024, primarily due to increased clinical development activities [17] - General and administrative expenses rose to $15.8 million in 2025 from $5.9 million in 2024, attributed to increased headcount and professional services [17] - The net loss attributable to common stockholders for 2025 was $41.7 million, or $3.71 per share, compared to a loss of $17.4 million, or $7.83 per share, in 2024 [17][20] Corporate Developments - The company successfully closed an oversubscribed public offering generating $230 million in gross proceeds, enhancing its financial position [4][12] - Palvella is focused on building a leading biopharmaceutical company addressing serious, rare skin diseases and vascular malformations with no FDA-approved therapies [4][14] - Recent leadership appointments aim to strengthen the company's market access and human resources capabilities [12]

Core Insights - Soligenix is entering a pivotal year with significant clinical and regulatory milestones, particularly the interim analysis of the Phase 3 FLASH2 trial for HyBryte™ in Q2 2026 and top-line results expected in H2 2026 [2] Recent Accomplishments - The European Commission granted orphan drug designation to dusquetide (SGX945) for Behçet's Disease on March 26, 2026, following a positive recommendation from the EMA [2] - Findings from supportive trials of HyBryte™ for CTCL were presented at the United States Cutaneous Lymphoma Consortium Workshop on March 23, 2026 [2] - A summary of clinical trials for HyBryte™ was published in the peer-reviewed journal Expert Opinion on Investigational Drugs on March 19, 2026 [2] - SGX945 received Promising Innovative Medicine designation in the UK for Behçet's Disease on March 10, 2026 [2] - The EMA COMP provided a positive recommendation for orphan drug designation for dusquetide on February 26, 2026, based on Phase 2a clinical results [2] Financial Results - Soligenix reported no revenues for the year ended December 31, 2025, compared to $0.1 million in the previous year, primarily due to the conclusion of a zero-margin grant for HyBryte™ [3] - The net loss for 2025 was $11.1 million, or ($2.14) per share, an increase from $8.3 million, or ($4.98) per share, in 2024, attributed to higher R&D costs and decreased other income [4] - Research and development expenses rose to $7.5 million in 2025 from $5.2 million in 2024, mainly due to costs associated with the Phase 2 study in Behçet's Disease and the ongoing Phase 3 CTCL study [5] - General and administrative expenses were $4.4 million in 2025, slightly up from $4.2 million in 2024, due to increased taxes and stock-related expenses [6] - As of December 31, 2025, the company's cash position was approximately $7.9 million [6]

Rising to the Challenges of Rare Disease Treatment NASDAQ: SNGX March 27, 2026 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products and product candidates and their development, regulatory approvals, ability to commercialize our products and product candidates and a ...

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][37] - Adjusted EBITDA margin improved to 29%, up from 18% in the prior year period, with GAAP net income of $1.5 million and non-GAAP net income of $5.4 million [6][45] - The company expects adjusted EBITDA margin to exceed 30% in 2026, with a full-year adjusted gross margin projected to be above 70% [39][45] Business Line Data and Key Metrics Changes - The launch of Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with Increlex seeing a rise in treated patients from 67 to over 100 since acquisition [12][13] - Alkindi and KHINDIVI showed strong growth, with Alkindi achieving its best year yet in terms of patient numbers and new referrals [17] - DESMODA, the newly launched oral liquid formulation of desmopressin, is expected to fulfill a large unmet need and has already seen significant traction in the market [8][10] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential patient base significantly beyond initial estimates [10] - Eton estimates a peak sales forecast of $30 million to $50 million for DESMODA, with initial demand being encouraging [11] - The company believes it has captured around 12% of the market for its adrenal insufficiency franchise, with a target of achieving at least $50 million in peak annual sales [18] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S., with a goal of reaching 13 or 14 commercial products [32] - The company plans to exit 2027 with a $200 million revenue run rate, driven by growth in existing products and potential new acquisitions [33] - Eton is focused on maintaining profitability while pursuing growth, with a target of reaching a 50% adjusted EBITDA margin by 2028 [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for 2026, expecting revenue to exceed $110 million [30] - The company highlighted the importance of executing its strategy and delivering consistent, profitable growth to reflect long-term value in its stock price [32] - Management noted that all areas of the business are functioning well, with strong growth prospects in the coming quarters [59] Other Important Information - Eton's acquisition of HEMANGEOL is expected to significantly enhance its product portfolio, with plans for a relaunch in May 2026 [20][25] - The company is implementing a new distribution model for HEMANGEOL to improve operational efficiency and patient access [23] - Eton has a strong pipeline of clinical studies planned for 2026, making it the busiest year in terms of clinical activities [30] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's peak sales timeline - Management expects the launch to peak sales to be quicker than previous products due to the specific unmet need it addresses [53] Question: Cash flow conversion from EBITDA in 2026 - Management confirmed that the company will be in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million run rate by end of 2027 - Management believes this goal is achievable based on the growth of existing products and potential new product deals [58][59]

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][37] - Adjusted EBITDA margin improved to 29% from 18% in the prior year period, with GAAP net income of $1.5 million and non-GAAP net income of $5.4 million [6][45] - The company expects adjusted EBITDA margin to exceed 30% in 2026, with a full-year adjusted gross margin projected to be above 70% [39][45] Business Line Data and Key Metrics Changes - Alkindi Sprinkles, Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with Increlex and Galzin performing beyond initial expectations [5][37] - The launch of DESMODA, an oral liquid formulation of desmopressin, is expected to fulfill a large unmet need and has already seen significant traction in the market [8][10] - The pediatric endocrinology portfolio, including Alkindi and KHINDIVI, continues to show strong growth, with Alkindi achieving its strongest year yet in terms of patient numbers [17][18] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential market size significantly beyond initial estimates [10] - Eton has captured approximately 12% of the estimated 5,000 children under eight in the U.S. with adrenal insufficiency, with a target of achieving at least 20% market share [18][19] - The company anticipates that HEMANGEOL could become one of its largest products by 2027, with an estimated 5,000-10,000 infants treated annually in the U.S. [20][25] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S. and has set new long-term goals, including reaching a $200 million revenue run rate by the end of 2027 [32][33] - The company plans to optimize the distribution model for HEMANGEOL and implement a patient support program to improve access and reduce costs [23][25] - Eton is focused on maintaining profitability while pursuing growth, with a goal of achieving a 50% adjusted EBITDA margin by 2028 [34][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of existing products and the successful integration of new acquisitions, including HEMANGEOL and DESMODA [31][32] - The company anticipates significant operating cash flow generation throughout 2026 and beyond, with a focus on disciplined cost management [46][47] - Management highlighted the importance of achieving label harmonization for Increlex to unlock additional market opportunities [15][70] Other Important Information - Eton's acquisition of HEMANGEOL was completed for $14 million in cash, avoiding dilution or incremental debt, which is expected to enhance earnings [25] - The company is preparing for a busy year in 2026 with multiple clinical studies planned, including those for KHINDIVI and ET-700 [30] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's peak sales timeline - Management expects the launch to peak sales to be quicker than previous products due to the specific unmet need it addresses [53][54] Question: Cash flow conversion from EBITDA in 2026 - Management confirmed that the company will be in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million revenue run rate by end of 2027 - Management is confident that existing products, including HEMANGEOL and DESMODA, will contribute significantly to achieving this goal [58][59]

Core Insights - The latest episode of The BioMedWire Podcast features Dr. Christopher Schaber, CEO of Soligenix Inc., discussing the company's Phase 3 FLASH2 study for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) [2][6]. Company Overview - Soligenix Inc. is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs [8]. - The company is advancing HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy for CTCL, with plans for potential commercialization following successful Phase 3 study completion [9]. Study Insights - The upcoming interim analysis of the Phase 3 FLASH2 study will assess safety and efficacy, with a focus on whether to continue patient enrollment or stop early for overwhelming efficacy [3][4]. - Initial assumptions for the study included a 40% response rate for HyBryte™ and 10% for placebo, leading to a conservative aggregate blinded response rate of 25% [5]. - At the 50-patient mark, the blinded aggregate response rate was reported at 48%, significantly exceeding initial expectations [5]. Future Outlook - The interim analysis and top-line results are anticipated to be transformational for the company, potentially leading to commercialization and partnerships for HyBryte™ [6]. - The company has conducted multiple positive studies leading up to this Phase 3 trial, indicating a de-risked development program [6].

Summary of Jaguar Health Conference Call Company Overview - **Company Name**: Jaguar Health (NasdaqCM: JAGX) - **Subsidiary**: Napo Pharmaceuticals - **Core Product**: Crofelemer, FDA-approved for chronic diarrhea in HIV/AIDS patients and conditionally approved for chemotherapy-induced diarrhea in dogs [2][3] Key Points Product and Market Position - Crofelemer is a first-in-class, plant-based, FDA-approved antisecretory agent with a robust intellectual property strategy, providing exclusivity [3] - The company has licensed Mytesi to Future Pak, generating substantial non-dilutive resources, including an $18 million upfront payment and potential future payments of up to $20 million [4][5] Pipeline Opportunities - Focus on late-stage clinical programs for rare diseases, specifically targeting intestinal failure indications such as pediatric congenital disorder, microvillus inclusion disease (MVID), and short bowel syndrome [6][7] - The short bowel syndrome market is projected to exceed $8 billion by 2033, with regulatory advantages for rare disease treatments [8] Clinical Trials and Results - Clinical proof of concept demonstrated reductions in parenteral support by up to 37% in MVID patients and 15.5% in short bowel syndrome patients [12] - The pivotal trial for MVID is fully enrolled, aiming for FDA filing by early 2027, with potential for Breakthrough designation [15][27] Competitive Landscape - Current treatment options for short bowel syndrome include Gattex, which has limitations and is not widely used [19][20] - Crofelemer aims to become the standard of care in intestinal failure, leveraging its established safety profile and manufacturing capabilities [20][22] Strategic Collaborations - The acquisition of Theratechnologies by Future Pak aligns with Jaguar's target demographic, enhancing the growth potential of Mytesi [30][31] - Collaboration is expected to accelerate revenue growth for Mytesi, particularly among long-term HIV survivors [31][32] Manufacturing and Supply Chain - Jaguar Health emphasizes the importance of manufacturing stability and supply chain management to meet potential demand for crofelemer across various indications [33][34] Additional Insights - The company is exploring opportunities in mental health treatments derived from its collection of 2,300 plants, with a focus on innovative therapies [26] - Regulatory communications with the FDA have been positive, indicating a collaborative approach to developing appropriate labeling for rare disease treatments [15][27] This summary encapsulates the key aspects of Jaguar Health's conference call, highlighting the company's strategic focus on rare diseases, clinical advancements, and market positioning.

Pharming Group N.V. Fourth quarter and full year 2025 financial results March 12, 2026 NASDAQ: PHAR | EURONEXT Amsterdam: PHARM CEO Fabrice Chouraqui Chief Executive Officer Introduction SPEAKERS Fabrice Chouraqui Chief Executive Officer Leverne Marsh Chief Commercial Officer Anurag Relan, MD Chief Medical Officer Kenneth Lynard Chief Financial Officer Forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that ar ...

Core Viewpoint - Santhera Pharmaceuticals reports a strong commercial momentum with AGAMREE, achieving 98% revenue growth in 2025, driven by increased adoption in European markets and strategic partnerships, positioning the company favorably in the rare disease sector [1][4]. Financial Performance - Total revenue for 2025 reached CHF 77.4 million, up from CHF 39.1 million in 2024, significantly exceeding the initial guidance of CHF 65–70 million [4]. - Product sales increased by 72% to CHF 25.8 million, reflecting strong AGAMREE adoption in Germany, Austria, and early sales in the UK [4]. - Royalties and milestones rose by 37% to CHF 23.1 million, driven by strong performance from licensing partner Catalyst Pharmaceuticals, including a USD 12.5 million sales milestone payment [4][7]. - Revenue from product and service supply to partners was CHF 28.5 million, up from CHF 7.2 million in 2024 [4]. Operational Highlights - AGAMREE's launch in the UK is progressing well, with uptake trends mirroring those in Germany [4]. - The company anticipates reaching cash flow breakeven in Q3 2026, with no additional funding required [4]. - Santhera entered into a strategic licensing agreement with Nxera Pharma for Japan and other APAC markets, valued at up to USD 205 million, including a USD 40 million upfront payment [4][5]. Market Expansion - Santhera has broadened its global access through new distribution partnerships in regions including GCC countries, India, Türkiye, and Russia [7]. - The company is targeting further launches across Europe in 2026, including Italy and Nordic markets, contingent on local regulatory processes [4]. Research and Development - Positive long-term data from the GUARDIAN study showed AGAMREE's efficacy comparable to standard corticosteroids, with an improved safety profile [7]. - The company plans to promote these findings to physicians, which is expected to enhance sales in 2026 [7]. Leadership and Governance - Santhera has strengthened its leadership team with new appointments, including a Chief Financial Officer and a Chief Commercial Officer, to drive future growth [7].

BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date of Conference**: March 11, 2026 - **Key Speakers**: Brian (CFO), Cristin (Chief Commercial Officer) Key Highlights of 2025 - **Revenue Growth**: Total revenue grew by 13% in 2025, with Voxzogo revenue increasing by 26% and enzyme therapies by 9% [2][3] - **Profitability Improvement**: Earnings per share growth outpaced revenue growth, achieving over 2 times leverage on the bottom line after adjusting for special items [3] - **Amicus Acquisition**: Announcement of the acquisition of Amicus, expected to close in Q2 2026, which will add two high-growth rare disease assets to BioMarin's portfolio [3][4] 2026 Outlook - **Revenue Guidance**: Expected revenue growth in both enzyme therapies and skeletal conditions at 7%-8%, with a total revenue headwind of about 3% due to decreasing royalty and other revenues [4] - **Voxzogo Revenue Guidance**: Projected revenue for Voxzogo in 2026 is between $975 million and $1.025 billion, influenced by international market access negotiations and competitive impacts [14][15] - **Pipeline Advancements**: Anticipated phase 3 readouts for hypochondroplasia and BMN 401, with potential for significant market impact [5][47] Competitive Landscape - **Voxzogo Competition**: Voxzogo faces competition, but only 25% of its revenues are from the U.S., which is subject to competition, representing about 7% of total revenue [8][15] - **Market Positioning**: BioMarin is confident in Voxzogo's established position in the achondroplasia community, emphasizing the complexity of switching treatments for patients [7][8] Clinical Pipeline - **Hypochondroplasia**: Estimated total addressable patient population of 14,000, with a focus on increasing disease awareness and shortening diagnosis times [24][25] - **BMN 351**: A second-generation exon skipping therapy for Duchenne muscular dystrophy, showing promising early data with a target of 10% dystrophin expression [6] - **ENPP1 Deficiency**: Anticipated phase 3 data readout for BMN 401, with an estimated addressable patient population of 2,000-2,500 globally [47][48] Amicus Acquisition Impact - **Revenue Contribution**: Amicus products generated over $600 million in 2025, expected to enhance BioMarin's revenue portfolio significantly [18] - **Operational Synergies**: Anticipated operational expense synergies from integrating Amicus, with a focus on leveraging existing global capabilities [30][32] Financial Strategy - **Deleveraging Plan**: Target to reduce debt to less than 2.5 times within two years post-acquisition, with a focus on maintaining operational profitability [56][57] - **Future Business Development**: Continued interest in pipeline clinical stage transactions to enhance long-term revenue growth [58] Additional Insights - **Palynziq Expansion**: Recent label expansion for Palynziq to include adolescents, with an estimated 1,500 eligible patients in the U.S. [39][41] - **Seasonality in Revenue**: Historical trends indicate a ramp-up in revenue towards Q4, with a typical step down in Q1 due to international order timing [49][50] This summary encapsulates the key points discussed during the BioMarin Pharmaceutical FY Conference, highlighting the company's growth trajectory, competitive positioning, and strategic initiatives for the upcoming year.